Showing 7481-7490 of 8465 results for "".
- NRS Releases New Free Resource for Rosacea Patientshttps://practicaldermatology.com/news/nrs-releases-new-free-resource-for-rosacea-patients/2460125/The National Rosacea Society new public service booklet, “Recognizing Redness”, is now available. The free booklet includes a redness register to allow patients to gauge relative redness
- Soliton Treats First Patients in Cellulite Trialhttps://practicaldermatology.com/news/soliton-treats-first-patients-in-cellulite-trial/2460124/The first patients in Soliton’s cellulite trial have been treated, the Company reports. "Patient treatments have now begun at the Chicago site,” says Dr. Chris Capelli, President, CEO and co-founder of Soliton, in a ne
- Nebraska Gets “SUNucated”https://practicaldermatology.com/news/nebraska-gets-sunucated/2460116/Nebraska is the latest state to recommend that children be allowed to possess and use sunscreen without a doctor’s note at school and at school-sponsored events. “I am thrilled that Nebraska is stepping up to the plate with commonsense information that will now be con
- Ortho Dermatologics Expands Cash-Pay Prescription Program with Walgreens Agreementhttps://practicaldermatology.com/news/ortho-dermatologics-expands-cash-pay-prescription-program-with-walgreens-agreement/2460115/Ortho Dermatologics’ Cash-Pay Prescription Plan is now available at Walgreen’s stores nationwide. Under the expanded agreement, Walgreens patients will have access to the select dermatology products included in Ortho Dermatologics’ first-of-its-kind cash-pay pres
- PE-Backed Ownership of Dermatology Practices Is On The Risehttps://practicaldermatology.com/news/pe-backed-ownership-of-dermatology-practices-is-on-the-rise/2460104/Private equity firms have increased their financial stakes in dermatology practices throughout the United States, but exactly how this affects care is not fully understood yet. Private equity-backed dermatology management groups acquired 184 dermatology practices from 2012 to 2018, with
- Modernizing Medicine: New Capabilities Address Price Transparency, Patient Engagementhttps://practicaldermatology.com/news/modernizing-medicine-new-capabilities-address-price-transparency-patient-engagement/2460100/Modernizing Medicine® will showcase new and enhanced capabilities for price transparency, digital patient engagement and more to the company’s electronic health records (EHR) platform, EMA®, and Practice Management system at the American Academy of Dermatology (AAD) 2019 S
- Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019https://practicaldermatology.com/news/psoriasis-psoriatic-arthritis-and-ad-updates-from-day-1-at-derm2019/2460098/The first day of the DERM2019 NP/PA CME Conference kicked off with a bang! Exciting talks and lively panel discussions from April Armstrong, David Cohen, Adam Friedman, Kara Gooding, and Joe Gorelick were the mainstay of the day. Psoriasis Pathogenesis and Treatment T
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- New to SENTE BOD: Clint Carnell and Clement Gingrashttps://practicaldermatology.com/news/new-to-sente-bod-clint-carnell-and-clement-gingras/2460093/SENTÉ has appointed Clint Carnell and Clement Gingras to its Board of Directors effective immediately. "We are thrilled to have both Clint and Clement join the SENTÉ team," says Faheem Hasnain, Chairman of t
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin